№ files_lp_3_process_9_39955
File format: docx
Character count: 21019
File size: 174 KB
Opioid overdose rescue training manual for facilitators, detailing the structure and content of a training session on recognizing and responding to opioid overdoses.
Year:
2024
Region / City:
Massachusetts
Topic:
Opioid Overdose Rescue and Prevention
Document Type:
Training Guide
Organization / Institution:
Health Resources in Action (HRiA), Massachusetts Department of Public Health
Author:
BeHERE Initiative
Target Audience:
Trainers and participants in overdose prevention training
Duration:
120 minutes
Approval Date:
April 2024
Date of Last Update:
April 2024
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / City:
Richmond, VA
Topic:
Opioid overdose, Naloxone
Document Type:
Instructional Guide
Organization:
Virginia Department of Behavioral Health and Developmental Services
Author:
N/A
Target Audience:
General public, individuals attending REVIVE! training
Effective Date:
N/A
Date of Last Revision:
September 2021
Year:
2025
Note:
Region / City
Topic:
Overdose Case Definitions
Document Type:
Guideline
Organization:
NEMSIS
Target Audience:
EMS Providers, Medical Personnel
Note:
Year
Theme:
Overdose Recognition, Naloxone, Opioid Epidemic
Document Type:
Training Material
Target Audience:
Community Health Workers/Representatives, CHW/R Managers, College/University Students, Community Leaders
Version:
April 24, 2024
Year:
2024
Region / City:
Ohio
Theme:
Emergency Department Overdose Reporting
Document Type:
Compliance Effort
Organization / Institution:
CliniSync, Ohio Department of Health
Author:
Phil Ennen
Target Audience:
Health Systems, Hospitals, Stakeholders in Ohio
Effective Date:
April 8, 2024
Date of Approval:
March 25, 2024
Date of Last Change:
February 2024
Year:
2022
Region / City:
United States
Topic:
Opioid overdose prevention, data collection, and evaluation
Document type:
Evaluation plan
Agency / Institution:
Centers for Disease Control and Prevention (CDC)
Author:
Centers for Disease Control and Prevention (CDC)
Target Audience:
State and local health departments, program implementers, stakeholders in overdose prevention
Period of validity:
2022–2026
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
Not specified
Region / City:
Not specified
Document Type:
Research Table
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Healthcare professionals, researchers
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2021
Region / City:
New Jersey
Subject:
Substance Use Disorders, Law Enforcement, Recovery Support
Document Type:
Public Notice
Institution:
Department of Law and Public Safety
Author:
Office of the Attorney General
Target Audience:
County Prosecutors, Law Enforcement, Recovery Specialists, Healthcare Partners
Period of Effectiveness:
September 1, 2021 - August 31, 2022
Approval Date:
N/A
Amendment Date:
N/A
Year:
2021
Region / City:
Kansas
Topic:
Overdose Fatality Review, Substance Use, Public Health
Document Type:
Meeting Minutes
Organization / Institution:
Kansas Department of Health and Environment (KDHE)
Author:
Ryan Lester, Adrienne Hearrell, Jennifer Donnelly, Julia Baughman, Krista Machado
Target Audience:
Public health professionals, healthcare providers, policy makers
Validity Period:
2021
Approval Date:
July 6, 2021
Modification Date:
Not mentioned
Year:
2020
Region / City:
United States
Topic:
Overdose Surveillance
Document Type:
Plan
Organization / Institution:
CDC
Author:
Centers for Disease Control and Prevention
Target Audience:
State and local governments, non-governmental organizations, healthcare providers, community-based organizations
Period of Validity:
Until completion of dissemination activities
Approval Date:
August 31, 2020
Revision Date:
None
Organization:
Centers for Disease Control and Prevention
Program:
Enhanced State Opioid Overdose Surveillance (ESOOS)
Version:
v1
Subject:
Opioid overdose syndrome definition
Document type:
Public health surveillance guidance
Scope:
Emergency department visit monitoring
Data sources:
ICD-9-CM, ICD-10-CM, SNOMED, chief complaint free text
Related organizations:
National Center for Health Statistics; Council of State and Territorial Epidemiologists; Substance Abuse and Mental Health Services Administration
Intended users:
ESOOS-funded state health departments
Geographic coverage:
United States
Limitations:
Cannot differentiate prescription from illicit opioid overdose; cannot distinguish fentanyl from fentanyl analogs
Organization:
Michigan Public Health Institute
Division:
MDHHS Division of Chronic Disease and Injury Control
Program:
MDHHS Prescription Drug Overdose: Data-Driven Prevention Initiative (PDO: DDPI)
Supervisor:
Jennifer DeLaCruz
Location:
Lansing area, Michigan
Funding Source:
Centers for Disease Control and Prevention grant
Position Type:
Exempt under the Fair Labor Standards Act
Primary Focus:
Prescription opioid and heroin overdose primary prevention
Key Responsibilities:
Program development, contract monitoring, grant reporting, budget oversight, stakeholder coordination, technical assistance
Education Requirement:
Master’s degree in public health, social work, or closely related health field
Experience Requirement:
Minimum one year experience in substance use disorder, health education, outreach, or project management
Collaborating Agencies:
Michigan Department of Health and Human Services; Department of Licensing and Regulatory Affairs
Work Requirements:
Significant travel; valid driver’s license; extensive computer use
Reporting Obligations:
Federal performance and financial reporting
Year:
2027
Region / Jurisdiction:
Maryland
Document Type:
Grant Program Application Form
Program:
Competitive Grant Program
Issuing Office:
Maryland’s Office of Overdose Response (MOOR)
Subject Area:
Overdose prevention, substance use disorder services, and public health initiatives
Strategic Priorities:
Prevention; Drug User Health; Treatment; Recovery; Public Safety
Eligible Project Areas:
Social determinants of health; adverse childhood experiences and trauma; evidence-based prevention; low-threshold services; risk reduction tools; overdose education and naloxone distribution; medications for opioid use disorder; barrier reduction in care; holistic care for people who use drugs; employment and recovery supports; community-based recovery; criminal justice health impact reduction; reentry service connections
Application Components:
Project Summary; Problem Statement; Program Measurement and Performance Indicators; Timeline; Budget Detail and Narrative; Program Sustainability Plan
Applicant Information Required:
Organization name, FEIN, point of contact, position, phone, email
Certification Requirement:
Applicant signature and confirmation of accuracy of submitted information
Administering Authority:
Maryland’s Office of Overdose Response
Year:
2026
Region / City:
Global
Subject:
Emergency treatment of opioid overdose
Document Type:
Pharmaceutical product monograph
Organization / Institution:
OPVEE™ Pharmaceuticals
Author:
OPVEE™ Research and Development Team
Target Audience:
Healthcare professionals and emergency responders
Dosage Form:
Nasal spray
Active Ingredient:
Nalmefene hydrochloride
Indications:
Treatment of known or suspected opioid overdose in patients 12 years and older
Pharmacokinetics:
Nasal administration, onset 2.5–5 minutes, duration ~6 hours above EC50
Safety Considerations:
Pregnancy, lactation, pediatric and geriatric usage, renal and hepatic impairment
Contraindications:
Hypersensitivity to nalmefene or other components
Adverse Effects:
Possible acute withdrawal in opioid-dependent patients, recurrence of respiratory depression
Jurisdiction:
Clay County, Missouri
Type of document:
Charter
Subject matter:
Opioid settlement fund governance
Purpose:
Advisory oversight and recommendations on opioid settlement fund allocation
Funding source:
Opioid Settlement Agreement
Total settlement amount:
Approximately $1,444,623.26
Funding period:
18 years
Annual allocation:
Approximately $80,000
Governing body:
Clay County Commission
Advisory body:
Clay County Opioid Settlement Task Force
Membership size:
9 members
Appointing authority:
Presiding Commissioner with consent of the Governing Body
Meeting openness:
Open to the public
Public notice law:
Missouri Open Records Act
Meeting location:
Clay County Administration, 1 Courthouse Square, Liberty, Missouri
Reporting requirement:
Formal report and proposed plan submitted to the Commission
Termination condition:
Approval of an opioid settlement utilization plan by the Clay County Commission
Year:
2023
Region / City:
Pinal County, Arizona
Topic:
Opioid Settlement Funding, Community Health Programs
Document Type:
Guidelines
Agency:
Pinal County Public Health Services District
Target Audience:
Nonprofit Organizations, Community-Based Organizations, Healthcare Providers
Period of Validity:
September 22, 2025
Approval Date:
July 12, 2023
Date of Changes:
-
Year:
2021
Region / City:
Richmond, VA
Topic:
Opioid overdose, Naloxone
Document Type:
Instructional Guide
Organization:
Virginia Department of Behavioral Health and Developmental Services
Author:
N/A
Target Audience:
General public, individuals attending REVIVE! training
Effective Date:
N/A
Date of Last Revision:
September 2021
Year:
2023
Country:
Australia
Topic:
Opioid dependence treatment
Document type:
Information overview
Program:
ODT Community Pharmacy Program
Administering body:
Pharmacy Programs Administrator
Related scheme:
Pharmaceutical Benefits Scheme
Legislative framework:
National Health (Highly specialised drugs program) Special Arrangement 2021
Target audience:
Community pharmacists and hospital pharmacists
Effective date:
1 July 2023
Funding period:
2023–24 to 2026–27
Medicines covered:
Methadone, buprenorphine, buprenorphine with naloxone
Regulatory classification:
Schedule 8 controlled drugs
Source type:
Government health program guidance
Year:
2025
Region / City:
Massachusetts, Boston
Topic:
Healthcare, Opioid Use Disorder, Long-Term Care
Document Type:
Memorandum
Organization / Institution:
Department of Public Health
Author:
Teryl Smith, RN, MPH
Target Audience:
Long-Term Care Facility Administrators
Period of Validity:
August 14, 2025
Approval Date:
August 14, 2025
Date of Changes:
August 14, 2025
Year:
2022
Region / City:
Massachusetts
Subject:
Opioid Use Disorder, Long-Term Care Facilities
Document Type:
Memorandum
Agency:
Massachusetts Executive Office of Health and Human Services, Department of Public Health
Author:
Elizabeth Kelley, MPH, MBA, Director Bureau of Health Care Safety and Quality
Target Audience:
Long-Term Care Facility Administrators
Period of Validity:
September 12, 2022
Approval Date:
September 12, 2022
Year:
2019–2020
Country:
England
Thematic area:
Opioid prescribing and medicines safety
Document type:
Technical specification
Related programme:
Prescribed Medicines Review
Issuing bodies:
NHS Business Services Authority; Wessex Academic Health Science Network
Contributing organisations:
Public Health England; Medicines and Healthcare products Regulatory Agency
Intended audience:
Healthcare professionals; NHS organisations
Data sources:
NHS prescribing data; Electronic Prescribing System
Medicine classifications used:
British National Formulary
Appendices included:
Medicine classes; Oral Morphine Equivalent values; Working groups